Direct evidence is thin. The claim is plausible and aligns with adjacent findings, but there isn't yet a body of high-quality work that would let us call it well-supported on its own terms.
is it safe to say we don't know when the ideal time to implement would be I think it depends a little bit on what you mean by ideal right so this now gets into risk reward and side effects versus benefits in mice we absolutely don't know in terms of lifespan if we take that as the sort of primary metric that we're interested in we don't know when is optimal to initiate treatment or what dosing protocol is optimal
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
so I think Peter we need better information under these sort of lower doses quasi intermittent with a feeding cycle to understand the answerers your question
it's never been dose optimized right
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.